Drug Trial Radar · NCT01785849
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
Last checked: Nov 20, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
508
Actual
Start
Mar 12, 2013
Primary completion
May 22, 2014
Study completion Jun 12, 2014
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
Conditions
- Hyperparathyroidism, Secondary
Interventions
EtelcalcetideDrug
Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
PlaceboDrug
Administered intravenously (IV) three times per week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment PhaseTime frame: Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).
Locations
118 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Pine Bluff, Arkansas
Research Site
Azusa, California
Research Site
Covina, California
Research Site
Lakewood, California
Research Site
Los Angeles, California
Research Site
Lynwood, California
Research Site
Northridge, California
Research Site
Ontario, California
Research Site
Panorama City, California
Research Site
Sacramento, California
Research Site
Whittier, California
Research Site
Pembroke Pines, Florida
Research Site
Meridian, Idaho
Research Site
Evanston, Illinois
Research Site
Springfield, Massachusetts
Research Site
Detroit, Michigan
Research Site
Kalamazoo, Michigan
Research Site
Pontiac, Michigan
Research Site
Southgate, Michigan
Research Site
Tupelo, Mississippi
Research Site
Kansas City, Missouri
Research Site
Reno, Nevada
Research Site
Amherst, New York
Research Site
Brooklyn, New York
Research Site
Rosedale, New York
Research Site
The Bronx, New York
Research Site
Yonkers, New York
Research Site
Chapel Hill, North Carolina
Research Site
Durham, North Carolina
Research Site
Allentown, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Orangeburg, South Carolina
Research Site
Sumter, South Carolina
Research Site
Columbia, Tennessee
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Fort Worth, Texas
Research Site
Fort Worth, Texas
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.